A pioneering therapeutic vaccine is offering new hope to patients battling aggressive brain tumors, according to long-term follow-up results published in the journal Nature. The clinical study, which tracked patients over an eight-year period, revealed that 66% of the participants were still alive after eight years, and 42% experienced no tumor recurrence during that timeframe.
The research was a collaborative effort involving scientists from the German Cancer Research Center, University Medical Center Mannheim, Heidelberg University Hospital, and other prominent research institutions. The clinical trial focused on 33 patients diagnosed with high-grade astrocytomas. These are highly aggressive brain tumors that typically carry an extremely high risk of returning after standard treatments, which usually consist of surgery, chemotherapy, and radiation. Currently, patients diagnosed with these aggressive tumors rarely survive past five years, as surgical removal is seldom fully complete.
Unlike preventive vaccines that prepare the immune system to ward off diseases like measles, mumps, or COVID-19, this therapeutic vaccine is designed to actively destroy existing tumors. Developed by a research team led by Michael Platten, the therapy targets a specific genetic mutation unique to certain brain tumors. The German Cancer Research Center explained that an identical genetic error alters a single amino acid in the IDH1 enzyme, creating a novel protein structure known as a neoepitope. This neoepitope simultaneously drives tumor growth and stands out as foreign to the patient’s immune system, making it a prime target for immunotherapy.
The experimental vaccine works by triggering a dual response from the immune system. It stimulates the production of T cells to directly attack the abnormal tumor cells and prompts B cells to generate antibodies against the tumor. Platten noted that the primary goal is to prevent the tumor from returning once standard radiochemotherapy is complete.
Ulrich Herrlinger, the director of neuro-oncology at the University Hospital Bonn, who was not involved in the study, described the findings as a genuine opportunity for patients. He pointed out that high-grade astrocytomas have an almost 100% likelihood of returning, continuing to grow, and eventually becoming untreatable, while the underlying causes of these tumors remain entirely unknown. Herrlinger expressed hope that keeping the immune system permanently active could suppress these tumors over the long term.
However, both Herrlinger and Platten urged caution against overinterpreting the current data. Herrlinger emphasized that definitive conclusions cannot be drawn from a small sample size of just 33 patients, noting that a controlled, randomized study is the necessary next step. Platten confirmed that such a study, set to involve more than 200 patients, is scheduled to begin in March 2027. He cautioned that it will take about nine years from today to obtain fully reliable results. Only then will it become clear how effective the vaccine really is and whether booster shots can further strengthen the immune response. Nevertheless, Platten says, the current study is reason for cautious optimism. Hope, he said, is something people can never have too much of.
"An identical genetic error causes a specific amino acid to be substituted in the IDH1 enzyme," the German Cancer Research Center explained in a press release. "This results in a novel protein structure — a so-called neoepitope. What makes this special is that, on the one hand, the neoepitope drives tumor growth — and, at the same time, it is recognized as foreign by the patient’s immune system, making it an ideal target for immunotherapies."
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
